Abeona Therapeutics (NASDAQ:ABEO) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a sell rating in a report issued on Saturday morning.

Other research analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Wednesday, February 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $5.50 on Friday. The firm has a market cap of $239.09 million, a price-to-earnings ratio of -2.04 and a beta of 1.43. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The company’s 50 day moving average is $5.64 and its 200 day moving average is $5.84.

Institutional Trading of Abeona Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. grew its stake in Abeona Therapeutics by 20.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after buying an additional 652,366 shares during the last quarter. Western Standard LLC boosted its holdings in Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after acquiring an additional 386,321 shares in the last quarter. Rosalind Advisors Inc. grew its stake in shares of Abeona Therapeutics by 4.7% during the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after acquiring an additional 82,000 shares during the last quarter. 683 Capital Management LLC increased its holdings in shares of Abeona Therapeutics by 17.3% during the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock valued at $4,411,000 after acquiring an additional 116,845 shares in the last quarter. Finally, Citigroup Inc. increased its holdings in shares of Abeona Therapeutics by 10.1% during the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after acquiring an additional 56,332 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.